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THE EFFICACY OF A STANDARDIZED ROSE-HIP POWDER
CONTAINING SEEDS AND SHELLS COMPARED WITH GLUCOSAMINE
SULFATE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE -
A BLINDED, PARALLEL, RANDOMIZED STUDY
A. Petcharat, K. Wongsuphasawat. Mae Fah Luang Univ., Bangkok,
Thailand
Purpose: Knee osteoarthritis is a degenerative disease caused by
imbalance between formation and the destruction of cartilage, having
pain, and crepitating knee as the most prominent symptoms. Rose-hip
powder (RHP) is a well-known herbal remedy in Northern Europe, and
glucosamine sulfate (GS) is commonly used to relieve symptoms of
knee osteoarthritis. The purpose of this study was to compare the
efﬁcacy of a standardized Rose-hip powder, manufactured by Hyben-
Vital, Langeland, Denmark, to glucosamine sulfate, in a blinded, parallel,
randomized, controlled study.
Methods: Patients with moderate to severe symptoms of knee osteo-
arthritis according to the criteria of the American College of Rheuma-
tology, without infectious arthritis, and not taking either of the studied
supplements for the last 6 weeks before entering the study, were
randomly recruited. Primary endpoints were to measure the efﬁcacy of
each remedy, and to compare the efﬁcacy of the two remedies, in the
reduction of symptoms from knee osteoarthritis such as pain, stiffness
and functional disability, measured by WOMAC score, at the end of 3rd,
5th and 8th week of treatment. The Secondary endpoints included the
reduction of analgesic consumption and the incidence of adverse
reactions at the end of the 8th week of treatment. Statistical evaluation:
WOMAC score changes within group were analyzed by Repeated
Measure two-ways ANOVA. Subanalysis of values between groups was
done by t-test. Data are given as mean values  SD. P value of less than
0.050 is regarded as statistical signiﬁcant.
Results: A number of 46 patients, 24 patients, 3 males 21 females, mean
age of 58.2510.76 years, mean weight of 62.208.85, with mean
WOMAC total score of 44.1711.87, were included in the GS group and
22 patients, 1male, 21 female, mean age of 60.4110.00, meanweight of
61.9910.56, with mean WOMAC total score of 44.5113.17, were
included in the RHP group. All completed the study. There was no
signiﬁcant difference in the subject characteristics between groups at
the initial level. Glucosamine sulfate (GS) was given at the dose of 1500
mg per day, while Rose-hip powder (RHP) was given at 4500 mg per
day. Results showed that, total WOMAC scores at the end of 3rd, 5th and
8th week in GS group declined with statistically signiﬁcance from
44.1711.87 to 33.9210.88 (p<0.001), 24.8312.16 (p<0.001), and
17.4612.11 (p<0.001), respectively, while the RHP group also showed
statistically signiﬁcant decrease in total WOMAC score from
44.5013.17 to 29.5915.86 (p<0.001), 19.3614.87 (p<0.001) and
9.5413.59 (p<0.001) respectively. The total WOMAC scores of RHP
group was signiﬁcantly lower than GS group at the end of the 8th week
(p<0.044). WOMAC scores on pain and stiffness also decreased signif-
icantly in both groups, without statistical signiﬁcant difference between
groups. The RHP group showed lower WOMAC score on functional
disability, with statistical signiﬁcance (P<0.015) when compared to GS
group at the end of the 8th week. Both groups were able to reduce the
use of analgesics at the end of 8th week, with no signiﬁcant difference
between groups. The GS group demonstrated more incidences of
adverse reactions (27 incidences, 15 cases) than the RHP group (16
incidences, 10 cases).
Conclusions: In conclusion, both GS and RHP were able to signiﬁcantly
reduce symptoms of knee osteoarthritis, such as pain and stiffness, after
3weeks of treatment. RHP showed better efﬁcacy than GS in term of total
WOMAC score reduction, and functional disability reduction at the end of
the 8th week, with less evidence and severity of adverse reactions.407
NEW FORMULATION WITH POTENTIAL FOR THE PREVENTION AND
TREATMENT OF OSTEOPOROSIS AND OSTEOARTHRITIS
A. Torrent y, E. Montell y, J. Vergés y, R. Ruhí z, P. Dalmau z, M.
Carceller x, A. Blanco x, M. Terencio x, M. Ferrándiz x, M.
Alcaraz x. y PharmaSci. Div., BIOIBERICA S.A., Barcelona, Spain;
z Technological Extraction Dept., BIOIBERICA S.A., Palafolls, Spain; xDept.
of Pharmacology and IDM, Univ. of Valencia, Burjassot, Spain
Purpose: Osteoarthritis (OA) is a multidimensional disease that affects
all anatomical joint structures, particularly cartilage, synovium andsubchondral bone. In turn, osteoporosis (OP) is a skeletal disorder
characterized by a compromised bone strength which substantially
increases the risk of fracture. Both are common disorders which affect
quality of life in the elderly. Despite this, there is not any drug at the
moment approved for the simultaneous prevention and treatment of
osteoporosis and osteoarthritis.
The aim of this study was to investigate the effect of a new formulation
in a combined rat model of OP and OA. The formulation (BIS076)
contains Vitamin D3, Hydroxyapatite as a source of calcium and
a natural extract from porcine cartilage. The latter is rich in bioactive
substances due to the mild conditions used in the manufacturing
process.
Methods: OP was induced by ovariectomy in female Wistar rats (180-
200g body weight, n¼ 15 rats/group) (week 0) and 2 weeks after (week
2) OA was induced by Anterior Cruciate Ligament Transection (ACLT).
All surgical procedures were carried out under deep anaesthesia with
isoﬂuorane (1.5 minimum alveolar concentration) which was followed
by the subcutaneous injection of butorphanol (2mg/kg). Animals were
maintained at a temperature of 212oC, with a 12 hour light/dark cycle
and with free access to food and tap water. BIS076 was administered
daily (oral gavage) at two doses from week 0 until week 12 after
ovariectomy. The low dose was 163.5 mg/kg/day and the high dose 245
mg/kg/day which correspond approximately to 1400 mg/day and 2100
mg/day in humans. A Control Group and an ovariectomized + ACLT
Group (Vehicle Group) were also included. After week 12, animals were
sacriﬁced. For the assessment of OA, histology was performed and
cartilage degeneration was evaluated by means of the OARSI score.
Synovitis degree was estimated according to the score proposed by
Krenn et al. Bone microarchitecture and density were assessed by
microCT.
Results: The preparation BIS076 has been shown to induce, at the 2
doses tested, a signiﬁcant reduction (approximately 50%) of the carti-
lage degradation according to the OARSI score. Synovial inﬂammation
was strongly reduced as well. In addition, microCT revealed that BIS076
treatment exerted a positive effect in bone structure, especially at the
high dose: Signiﬁcant increase in bone volume (p<0.05), bone surface
density (p<0.01), trabecular number (p<0.01) and signiﬁcant reduction
in the trabecular bone pattern factor (p<0.01) compared to the Vehicle
Group.
Conclusions: Our data demonstrate that treatment with BIS076 could
be an effective strategy to control the progression of experimental
Osteoarthritis and Osteoporosis. This approach holds promise for the
development of improved therapies targeting these chronic and
disabling diseases.408
THE ANTI-INFLAMMATORY CAPACITY OF ROSE-HIP IS STRONGLY
DEPENDENT ON THE SEEDS - A COMPARISON OF ANIMAL AND
HUMAN STUDIES
C. Marstrand y, L. Warholm z, A. Kharazmi x, K. Winther k. yDept. of
Orthopaedic Surgery, Horsens Hosp., Horsens, Denmark; zDept. of
Trauma and Acute Med., Horsens Hosp., Horsens, Denmark; xDept. of
Microbiol., RigsHosp.et, Copenhagen, Denmark; kDept. of Clinical
Biochemistry, Frederiksberg Hosp., Frederiksberg, Denmark
Purpose: A standardized preparation from selected subspecies of rose-
hip, developed and produced on Langeland, Denmark, trade name
Hyben-Vital, has drawn increasing attention as an anti-inﬂammatory
agent and a meta-analysis indicate that the remedy can alleviate
symptoms of osteoarthritis. The powder consists of an equal amount of
shells and seeds. The purpose of this study was to evaluate if the anti-
inﬂammatory capacity is dependent on seeds.
Methods: The clinical studies were double-blinded, placebo-controlled
and randomized and lasted from 3 to 6 month. Blood samples for
laboratory analysis were drawn initially and after at least 3 month
treatment. As the in vivo inﬂammatory marker, C-reactive protein (CRP)
is not well established in animal models we used, chemotaxis, a modi-
ﬁed Boyden chamber technique, to measure migration of poly-
morphnucleated cells (PMN`s) to the inﬂammatory sites. Inhibition of
migration indicates anti-inﬂammatory property. The methodology is
well established and results in comparable data when testing different
animal species including horses and dogs. In studies on humans we
measured CRP, using normal laboratory routine, at the initial level and
again after 3 to 6 month of treatment. In the animal study, two different
preparations of Rose-hip powder were used: One version of powder
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containing 70% of shells and 30% of seeds (by weight). All animals 16
dogs and 16 horses were treated for a time period of three month, the
dose was 0.3 g pr kg daily, and data was lumped together. The human
studies also tested two different versions of the same shell and seed
containing Rose-hip remedy: The daily dose of one version was 1.2 g
seeds and a similar amount of shells (A version) and the daily dose of
the version (B) was 0.2 g seeds combined with 1.8 g shells.
The human study was performed in two groups of middle aged patients
with modest osteoarthritis. A seasonal variation is reported for CRP
(higher during winter), and both groups started treatment late autumn.
A number of 43 patients were given high dose seed version and 40 other
patients were given corresponding placebo. Another group of 32
patients (B group) were given the low seed version and corresponded to
30 patients on placebo. Data given are mean +/- SD. Wilcoxon test for
matched pairs was used within groups and Mann-Whitney when
comparing placebo and active treatment. A p level less than 0.050 was
regarded as statistically signiﬁcant.
Results: Treatment with the high seed level resulted in a statistically
signiﬁcant reduction in chemotaxis from 28.6 +/- 13.5 to 5.6 +/- 3.4 in
a group of eight animals (p<0.010). A modest and insigniﬁcant increase
was observed in a placebo group of identical magnitude, p <0.050
comparing the two groups. The low dose seed preparation, when tested
in another eight animals resulted in an insigniﬁcant 3% increase of
chemotaxis (p<0.830). No change in chemotaxis was observed in the
placebo group and therewere no signiﬁcant difference between groups.
Patients reaction to the high seed and low seed preparation supported
the observations from animal studies. Treated with the A version (1.2 g
seeds daily) resulted in a insigniﬁcant CRP reduction from 2.07 +/- 2.19
to 1.68 +/- 1.28 mg/l, a reduction of 18%. In the placebo group CRP levels
increased statistically signiﬁcant from 1,43 +/- 0.91 to 1.89 +/- 1.35 mg/l
(p<0.014) an increase which is most likely due to reported seasonal
variation. The two groups were signiﬁcantly different from each other
as indicated by a Mann-Whitney p value of 0.042. In the B group
receiving low dose seed treatment (0.2 g daily) there was a modest and
insigniﬁcant increase of 20% in CRP levels, which was not signiﬁcantly
different when compared to observations from the corresponding
placebo group (p<0.339).
Conclusion: The present data suggest that Rose-hip seeds are of
importance to keep the optimal anti-inﬂammatory proﬁle in Rose-hip
preparations.409
AN ORAL PREPARATION CONTAINING HYLAURONIC ACID
(ORALVISC) CAN NORMALIZE THE TURNOVER OF HYALURONIC
ACID IN SYNOVIAL FLUID OF OSTEOARTHRITIC KNEE PATIENTS
K.W. Li y, W. Wu z, C.L. Emson y, S.M. Turner y, R. Zvirbulis z, F. Nelson z, D.
Martinez-Puig x. yKineMed, Inc, Emeryville, CA, USA; zBone and Joint Ctr.,
Henry Ford Hosp., Detroit, MI, USA; xBioiberica S.A., Palafolls, Spain
Purpose: Osteoarthritis (OA) is a degenerative joint disease in which
articular cartilage matrix is no longer in homeostatic balance, resulting
in a net loss of chondroitin sulfate (CS)-rich glycosaminoglycans (GAGs).
The pro-inﬂammatory environment of synovial ﬂuid has been shown to
result in an increase in hyaluronic acid (HA) turnover. Consequently the
turnover of CS and HA are considered key parameters to evaluate the
degree and evolution of OA. We conducted a double blind randomized
clinical trial to determine if there would be changes in turnover of CS
and HA in the synovial ﬂuid (SF) of knee OA patients treated with
a patented hyaluronic acid formulation for oral use (Oralvisc) as
compared to placebo.
Methods: 51 symptomatic knee OA patients were recruited sequentially
at the time of an outpatient visit for OA. Subjects were between the ages
of 50-75 years, had knee effusion, and a pain visual analog score (VAS)
>50mm. 40 patients completed the study, 21 had been randomly
selected to receive 80 mg daily of Oralvisc, and the remaining 19 had
identical appearing placebos. Each month they were evaluated for VAS
and WOMAC pain and joint function. A subset of 10 subjects per
treatment group began a 2-day long oral administration of heavy water
(35 mL 2H2O TID for 2 days) at the conclusion of the treatment phase
(Week 12), followed by a synovial ﬂuid aspiration in the affected knee.
Synovial ﬂuid lavage samples were analyzed for 2H-labeling of
component GAGs by gas chromatography/ mass spectrometry (GC/MS)
to obtain fractional synthesis rates of HA and CS in SF.Results: The age, sex, race, BMI, KL scores, as well as VAS pain and
WOMAC function were balanced between groups at the beginning of
the trial. Treatment with oral HA during 3 months resulted in a signif-
icant improvement in VAS pain (p¼0.0035), WOMAC pain (p¼0.0259)
and WOMAC function (p¼0.0132) compared to placebo. The stable-
isotope-mass spectrometry method was successfully implemented for
the clinical study of SF GAG kinetics. The rate of HA turnover was
0.780.42 / day (i.e., 78% per day) in placebo-treated OA patients (n¼10;
Fig. 1). With 12 weeks of oral HA treatment, the mean rate of HA
turnover declined by 45% to 0.420.24 / day (p¼ 0.046). While we have
not directly compared the rate of HA turnover in normal vs. osteoar-
thritic knees, comparison of the current results with data from
a previous study in ACL patients suggests that these osteoarthritis
patients (0.78 / d) have elevated HA turnover relative to “normal”
subjects (0.25 / d), and that oral HA partially normalized the HA turn-
over rate. CS molecules in the SF were also highly enriched, with the
majority of the patients recording the maximum measureable turnover
rate for this assay (>140% / day). Thus, virtually all of the SF-derived CS
was recently synthesized, suggesting a defect in the retention of
potential repair molecules in osteoarthritic cartilage.
Conclusions: This is the ﬁrst study of its kind to show that the use of an
oral HA (Oralvisc) agent in knee OA patients can lead to a signiﬁcant
impact on HA turnover in synovial ﬂuid. The normalization in HA
turnover was paralleled by an overall decrease in pain scores and
improvement in joint function. Further studies are needed to investi-
gate its mechanism but this novel form of oral HA may provide a safe
alternative treatment to correct the homeostatic imbalances in the
progression of OA.
Figure 1. Turnover rate of HA in the knee synovial ﬂuid of osteoarthritic patients. Bar
shows the group mean (ANOVA p ¼ 0.046).
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SULFORAPHANE REPRESSES MATRIX-DEGRADING PROTEASES AND
PROTECTS CARTILAGE FROM DESTRUCTION IN VITRO AND IN VIVO
R.K. Davidson y, O. Jupp y, R. de Ferrars y, C.D. Kay y, K.L. Culley y, R.
Norton y, C. Driscoll z, T.L. Vincent z, S.T. Donell y, Y. Bao y, I.M.
Clark y. yUniv. of East Anglia, Norwich, United Kingdom; zKennedy Inst.
for Rheumatology, Oxford, United Kingdom
Purpose: Broccoli is rich in glucoraphanin (a glucosinolate). When
broccoli is cut or chewed, glucoraphanin is converted by an enzyme,
myrosinase, to sulforaphane (an isothiocyanate). Similar compounds
are derived from other cruciferous vegetables and these compounds are
therefore accessible via the diet. Sulforaphane (SFN) has been reported
to regulate signalling pathways relevant to chronic diseases. Our study
investigated whether sulforaphane can abrogate cartilage destruction
in osteoarthritis and examined mechanism of action in chondrocytes.
Methods: The bovine nasal cartilage explant model (BNC) and desta-
bilisation of medial meniscus (DMM) murine model of osteoarthritis
were used to study chondroprotection by SFN. Histone acetylation, gene
expression, transcription factors nuclear factor (erythroid-derived 2)-
like 2 (Nrf2) and nuclear factor kappaB (NF-kB) signalling were
examined.
